U.S. research team makes initial breakthrough in new crown virus vaccine

U.S. research team makes initial breakthrough in new crown virus vaccine
The research team is working in the laboratory (picture provided by the University of Queensland). Brisbane, Feb. 25 (Wang Quanjiao) Under the current epidemic of new crown pneumonia, many research institutions around the world are actively developing related vaccines.Recently, a research team from the University of Queensland Victoria has made breakthrough progress in vaccine development.The University of Queensland announced on January 24 that it is using a patented technology to rapidly produce a vaccine against the new coronavirus.This is one of the rapid response projects of the International Organization “Epidemic Prevention and Innovation Alliance”.On February 22, the University of Queensland stated that the research team made a major breakthrough in the development of a new crown pneumonia vaccine.During the past three weeks, the research team initially produced the first vaccine in the laboratory.As more tests are performed, formal preclinical testing is available.According to Professor Paul Young, one of the leaders of the research team, the patented “molecular clamp” technology used by the team to develop vaccines can increase the stability of viral proteins, make the vaccine more easily recognized by the immune system, and stimulate a protective immune response.The project is Australia’s only new coronavirus vaccine research project initiated by the Epidemic Prevention Innovation Alliance.Paul Young said in an interview that the entire team had about 20 researchers.The team made several attempts to develop a preliminary vaccine.When the effort pays off, the team is excited.Scientists around the world are currently cooperating in a large number to work together to overcome the new crown pneumonia.The University of Queensland research team is proud to be one of them.He said the research team will then use mice for formal preclinical experiments.If the preclinical test results are positive, human testing can begin in the second half of 2020.If all goes well, hopefully the vaccine can be used within 12 to 18 months, which has a long way to go.Paul Young also said that the research team is very concerned about people affected 杭州夜网论坛 by new coronary pneumonia.”As scientists, we will work to change the world and continue to accelerate the pace of clinical testing in the second half of the year.”